$PRGO (Perrigo Company Public Limited Company)

$PRGO {{ '2016-05-12T12:09:09+0000' | timeago}} • Infographic

$PRGO Q1 2016 Earnings Infographic.

$PRGO {{ '2017-09-21T14:01:01+0000' | timeago}} • Announcement

Healthcare firm $PRGO said the FDA has approved the Abbreviated New Drug Application for its painkiller Exalgo-32mg. Perrigo expects to launch the Exalgo-32mg extended-release tablets by the end of this month. Exalgo is indicated for the management of moderate to severe pain in opioid-tolerant patients.

$PRGO {{ '2017-09-18T13:18:23+0000' | timeago}} • Announcement

$PRGO has received tentative approval from the US FDA for the generic version of Acanya topical gel 1.2%/ 2.5%, for the topical treatment of acne in patients 12 years or older.

$PRGO {{ '2017-08-21T17:07:39+0000' | timeago}} • Announcement

$PRGO got the final nod from the FDA for the store brand OTC equivalent of Nexium 24HR (esomeprazole magnesium) capsules, to treat frequent heartburns occurring 2 or more days a week.  It also reached a settlement of patent litigation with AstraZeneca allowing for the store brand OTC equivalent of Nexium 24HR capsules to launch in Sept, 2017.

$PRGO {{ '2017-08-16T13:22:34+0000' | timeago}} • Announcement

$PRGO received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Mycolog II Cream. This is indicated for the treatment of cutaneous candidiasis, which is a skin fungal infection causing a red, itchy rash. $PRGO anticipates launching this product in 4Q17.

$PRGO {{ '2017-08-10T17:56:52+0000' | timeago}} • Infographic

$PRGO Perrigo Company plc Earnings AlphaGraphic: Q2 2017 Highlights

$PRGO {{ '2017-08-10T13:57:06+0000' | timeago}} • Webcast

$PRGO is looking for operating margin of 40% for full year 2017, and expects to leverage its expanding product portfolio to achieve it. The company attributes the margin turnaround in its Consumer Healthcare International Segment in 2Q17 to the restructuring carried out in the first half.

$PRGO {{ '2017-08-10T13:22:29+0000' | timeago}} • Webcast

$PRGO repurchased about 812,000 shares in 2Q17. The 2017 sales outlook of business segments have been revised up to reflect new product launches and favorable currency movements. Perrigo expects to close the sale of its API business segment in the second half. Accordingly, the company removed adjusted operating income of $10MM from its guidance.

$PRGO {{ '2017-08-10T13:06:31+0000' | timeago}} • Webcast

$PRGO said various measures adopted by the company in the first half of 2017 will result in a total debt pay down of about $2.6Bil by the end of the year, and further debt reduction in the coming years.  The debt pay down actions resulted in an increase in cash flows, which would be used for returning capital to shareholders in future.

$PRGO {{ '2017-08-10T11:11:29+0000' | timeago}} • Announcement

$PRGO’s Consumer Healthcare Americas division recorded net sales of $605MM in 2Q17, down 4% compared to 2Q16. Sales of the Healthcare International segment dropped 9% YoY, and those of the Prescription Pharmaceuticals division fell 13%.

$PRGO {{ '2017-08-10T11:06:30+0000' | timeago}} • Announcement

$PRGO expects to record GAAP earnings of $0.84-$1.09 per share in calendar year 2017. The company now estimates its full year adjusted earnings to be in the range of $4.45 to $4.7 per share, which includes  the removal of about $0.05 per share related to the sale of the API business in second half.

$PRGO {{ '2017-08-10T10:58:21+0000' | timeago}} • Announcement

Consumer goods firm $PRGO reported a net loss of $70MM or $0.49 per share in 2Q17, significantly lower than the $534.3MM or $3.73 per share loss registered a year earlier. The improvement was the result of strong performance by all segments. On a non-GAAP basis, the company posted a net income of $70MM. Net sales decreased 8% annually to $1.2Bil.

$PRGO {{ '2017-08-08T19:41:55+0000' | timeago}} • Announcement

$PRGO has declared a quarterly dividend of $0.16 per share, payable on Sept 12, 2017 to shareholders of record as on Aug 25, 2017.

$PRGO {{ '2017-08-04T13:52:01+0000' | timeago}} • Announcement

$PRGO received tentative approval from the U.S. FDA for the generic version of Mirvaso (brimonidine) topical gel 0.33%. The company settled litigation with Galderma Laboratories and Nestle Skin Health S.A. for this product earlier. Mirvaso is indicated for the topical treatment of persistent erythema of rosacea in adults 18 years of age or older.

$PRGO {{ '2017-07-19T14:24:45+0000' | timeago}} • Announcement

$PRGO received final approval from the US FDA for its AB rated ANDA referencing DermOtic Oil, 0.01% Ear Drops. The company expects to launch this product within 90 days. DermOtic Oil, 0.01% Ear Drops are indicated for the treatment of chronic eczematous external otitis in adults, and children two years old and older.

$PRGO {{ '2017-07-17T13:30:02+0000' | timeago}} • Announcement

$PRGO received final approval from the FDA for its AB rated Abbreviated New Drug Application referencing $ABBV's Androgel Topical Gel, 1.62% packets. The gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

$PRGO {{ '2017-07-17T13:28:38+0000' | timeago}} • Announcement

$PRGO's subsidiary filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic version of Soolantra (ivermectin) cream, 1%. The cream is indicated for the treatment of inflammatory lesions of rosacea.

$PRGO {{ '2017-06-21T12:47:31+0000' | timeago}} • Announcement

$PRGO launched its generic equivalents to Hill Laboratories Inc.'s Derma-Smoothe/FS Scalp Oil and Derma-Smoothe/FS Body Oil. These are indicated for the topical treatment of atopic dermatitis in adult patients and the topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to four weeks.

$PRGO {{ '2017-06-14T17:53:40+0000' | timeago}} • Announcement

$PRGO announced the reference yield and total consideration for each series of notes subject to the previously announced cash tender offer for up to a combined aggregate principal amount of $1.4Bil of Perrigo's notes.

$PRGO {{ '2017-06-14T12:01:20+0000' | timeago}} • Announcement

$PRGO announced the early tender results as of June 13, 2017 for cash tender offer for up to combined amount of $1.4Bil of  4% Notes due 2023 and 5.3% Notes due 2043 and Perrigo Finance Unlimited's subsidiary 3.5% Notes due March 2021, 3.5% Notes due December 2021, 4.9% Notes due 2044, 4.375% Notes due 2026 and 3.9% Notes due 2024.

$PRGO {{ '2017-06-06T13:09:31+0000' | timeago}} • Announcement

$PRGO announced the forthcoming retirement of CEO John Hendrickson. Hendrickson will continue to stand for election to its BoD at its Annual General Meeting on July 20, 2017 and will step down from the Board upon the appointment of a new CEO.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, October 17 2017 - 12:45pm
JNJ (Johnson & Johnson)
Tuesday, October 17 2017 - 12:30pm
PRGO (Perrigo Company Public Limited Company)
Thursday, August 10 2017 - 12:00pm
VRML (Vermillion, Inc.)
Wednesday, August 9 2017 - 8:30pm
MYL (Mylan N.V.)
Wednesday, August 9 2017 - 2:00pm
MDCO (The Medicines Company)
Wednesday, August 9 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
ATRS (Antares Pharma Inc.)
Tuesday, August 8 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
AMRN (Amarin Corporation plc)
Wednesday, August 2 2017 - 12:00pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm

AlphaGraphics you may like